Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 39, Issue 1-2, Pages 17-23Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1040-8428(01)00120-2
Keywords
glioblastoma; IL-2; immunotherapy; interleukin-2; LAK; lymphokine-activated killer cells; malignant glioma; survival
Categories
Ask authors/readers for more resources
We report the successful treatment of a patient with recurrent malignant glioma with adoptive cellular immunotherapy. The patient is a young adult with recurrent progressive disease refractory to aggressive multi-modality therapy including repetitive surgical resection, radiation, radiosurgery and chemotherapy. He received multiple courses of local administration of autologous lymphokine-activated killer (LAK) cells in combination with a low dose of interleukin-2 (IL-2) through an Ommaya reservoir-catheter system. The side-effects of this treatment were limited and manageable. The patient achieved a complete remission, as demonstrated by MRI and confirmed by glucose-positron emission tomography (PET) imaging 11 months after initiation of immune therapy. Twenty-six months later, the patient is still in remission with improving performance status. Adoptive cellular immunotherapy utilizing autologous LAK cells with low dose IL-2 appears to be a safe and effective therapy for a subset of patients with primary, recurrent or progressive malignant glioma following conventional therapy. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available